A Phase 3 interventional study of Ixekizumab and Placebo in Genital Psoriasis and Psoriasis, sponsored by Eli Lilly and Company. Completed at 34 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-16.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 12th largest by enrollment, is one of 3 that started in 2016, is one of 11 in phase 3, and was the 11th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 20th largest by enrollment, is one of 5 that started in 2016, is one of 15 in phase 3, and was the 15th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe genital psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinded Treatment Period: 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab every 2 weeks (Q2W) SC from week 2 to week 10. At week 12, 80 mg ixekizumab and placebo given SC. Open Label Period: 80 mg ixekizumab given SC every 4 weeks (Q4W) with an option for Q2W dosing starting at week 24, week 28 or week 40.
Drug: Ixekizumab · Drug: Placebo
Blinded Treatment Period: Placebo given SC at baseline followed by placebo given SC Q2W from week 2 to week 10. At week 12, 160 mg ixekizumab given SC. Open Label Period: 80 mg ixekizumab given SC Q4W with an option for Q2W dosing starting at week 24, week 28 or week 40.
Drug: Ixekizumab · Drug: Placebo
Administered SC
Also known as: LY2439821
Administered SC
Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1)
sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.
Time frame: Week 12
Number of Participants Achieving Overall sPGA (0,1)
The overall sPGA is the physician's global assessment of the participant's psoriasis (Ps) lesions at a given time point. Plaques were assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity was given using the anchors of 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. Overall sPGA (0,1) : An overall sPGA assessed as either 0 or 1.
Time frame: Week 12
Number of Participants With at Least a 3 Point Improvement in Genital Psoriasis Itch Numeric Rating Scale (NRS) Item Within the Genital Psoriasis Symptom Scale (GPSS)
GPSS is a participant-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (= no severity) and 10 (worst imaginable severity).
Time frame: Week 12
Number of Participants Whose Frequency of Sexual Activity is Never or Rarely Limited by Genital Psoriasis, Utilizing the Genital Psoriasis Sexual Frequency Questionnaire (SFQ) Item 2
The SFQ is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual frequency. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Respondents were asked to answer the questions based on their psoriasis symptoms in the genital area. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with the following response options: 0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = always. \*The SFQ is also referred to as the GenPs-SFQ (genital psoriasis sexual frequency questionnaire).
Time frame: Week 12
Number of Participants Whose Frequency of Avoiding Sexual Activity is Either Never or Rarely Limited by Genital Psoriasis in the Sexual Activity Avoidance Subscale Score of the Genital Psoriasis Sexual Impact Scale (GPSIS)
GPSIS is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual activity. The GPSIS Sexual Activity Avoidance Subscale includes 2 items: Item 1 asks whether the participant has been sexually active in the past week. (No due to other reasons = 1, No due to genital Ps = 5) Item 2 asks how often the participant avoided sexual activity in the past week due to Genital Psoriasis. (Never = 1, rarely = 2, Sometimes = 3, Often = 4)
Time frame: Week 12
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: 1) Symptoms and feelings 2) Daily activities 3) Leisure 4) Work and school 5) Personal relationships 6) Treatment. Response categories include: 0 = not at all; 1 = a little; 2 = a lot; 3 = very much; "not relevant" responses scored as "0" and total score range of 0 to 30; higher scores indicate poor quality of life. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, baseline body surface area (BSA) category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
Time frame: Baseline, Week 12
Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score
mGPASI determines participants psoriasis severity in the genital region at a given time point yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. scoring index incorporates the degree of erythema (or redness), induration (or thickness), and scaling) of the genital plaques as well as erosion, fissure, and/or ulcer as a product of the genital area involved. LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
Time frame: Baseline, Week 12
Number of Participants With at Least a 2-Point Change in Patient's Global Assessment of Genital Psoriasis (PatGA-Genital)
Patient's Global Assessment of Genital Psoriasis (PatGA-Genital) is a participant-administered, single-item scale on which participants are asked to rank the severity of their genital psoriasis "today" by circling a number on a 0 to 5 NRS, as follows: from 0 (clear), no genital psoriasis; to 5 (severe).
Time frame: Week 12
Change From Baseline on the Short-Form Health Survey (SF-36) Physical Component Summary (PCS)
SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, \& baseline value and modified baseline observation carried forward (mBOCF) imputation method.
Time frame: Baseline, Week 12
Change From Baseline on the Short-Form Health Survey (SF-36) Mental Component Summary (MCS)
SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the MCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, \& baseline value and modified baseline observation carried forward (mBOCF) imputation method.
Time frame: Baseline, Week 12
Change From Baseline in Genital Psoriasis Symptom Scale (GPSS) Total Score and Individual Items
GPSS is a participant's-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (no severity) and 10 (worst imaginable severity). total score ranges from 0 (no severity) - 80 (worst imaginable severity) LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
Time frame: Baseline, Week 12
Number of Participants Achieving sPGA of Genitalia (0,1) at Week 12 by Treatment-Emergent Anti-Drug Antibody (TE-ADA) Status and by Neutralizing Antibody (NAb) Status
sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.
Time frame: Week 12
| Milestone | Placebo - Blinded Treatment | Ixekizumab 80mg Q2W - Blinded Treatment | Placebo/Ixekizumab 80mg Q4W - Open Label Treatment Period | Ixekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label Treatment | Placebo - Post Treatment Follow-up | Ixeqizumab 80mg Q4W - Post Treatment Follow-up Period | Ixekizumab 80mg Q2W - Post Treatment Follow-up |
|---|---|---|---|---|---|---|---|
| Started | 74 | 75 | 0 | 0 | 0 | 0 | 0 |
| Completed | 65 | 74 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 9 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 5 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo - Blinded Treatment | Ixekizumab 80mg Q2W - Blinded Treatment | Placebo/Ixekizumab 80mg Q4W - Open Label Treatment Period | Ixekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label Treatment | Placebo - Post Treatment Follow-up | Ixeqizumab 80mg Q4W - Post Treatment Follow-up Period | Ixekizumab 80mg Q2W - Post Treatment Follow-up |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 65 | 74 | 0 | 0 | 0 |
| Completed | 0 | 0 | 62 | 64 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 3 | 10 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Subject discontinued in oltp | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Ttt of undisclosed addiction-pt withdrew | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Placebo - Blinded Treatment | Ixekizumab 80mg Q2W - Blinded Treatment | Placebo/Ixekizumab 80mg Q4W - Open Label Treatment Period | Ixekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label Treatment | Placebo - Post Treatment Follow-up | Ixeqizumab 80mg Q4W - Post Treatment Follow-up Period | Ixekizumab 80mg Q2W - Post Treatment Follow-up |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 1 | 78 | 49 |
| Completed | 0 | 0 | 0 | 0 | 0 | 67 | 44 |
| Not completed | 0 | 0 | 0 | 0 | 1 | 11 | 5 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 1 | 5 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 5 | 3 |
sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.
| Participants | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Number of Participants Achieving Static Physician Global Assessment (sPGA) of Genitalia (0,1) | 6 | 55 |
The overall sPGA is the physician's global assessment of the participant's psoriasis (Ps) lesions at a given time point. Plaques were assessed for induration, erythema, and scaling, and an overall rating of psoriasis severity was given using the anchors of 0 = clear, 1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. Overall sPGA (0,1) : An overall sPGA assessed as either 0 or 1.
| Participants | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Number of Participants Achieving Overall sPGA (0,1) | 2 | 55 |
GPSS is a participant-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (= no severity) and 10 (worst imaginable severity).
| Participants | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Number of Participants With at Least a 3 Point Improvement in Genital Psoriasis Itch Numeric Rating Scale (NRS) Item Within the Genital Psoriasis Symptom Scale (GPSS) | 5 | 37 |
The SFQ is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual frequency. It consists of 2 items that assess the impact of genital psoriasis symptoms on the frequency of sexual activity. Respondents were asked to answer the questions based on their psoriasis symptoms in the genital area. Item 2 assesses how often genital psoriasis symptoms limited the frequency of sexual activity with the following response options: 0 = never, 1 = rarely, 2 = sometimes, 3 = often, 4 = always. \*The SFQ is also referred to as the GenPs-SFQ (genital psoriasis sexual frequency questionnaire).
| Participants | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Number of Participants Whose Frequency of Sexual Activity is Never or Rarely Limited by Genital Psoriasis, Utilizing the Genital Psoriasis Sexual Frequency Questionnaire (SFQ) Item 2 | 9 | 29 |
GPSIS is a participant reported outcome measure to evaluate the impact of genital psoriasis symptoms on sexual activity. The GPSIS Sexual Activity Avoidance Subscale includes 2 items: Item 1 asks whether the participant has been sexually active in the past week. (No due to other reasons = 1, No due to genital Ps = 5) Item 2 asks how often the participant avoided sexual activity in the past week due to Genital Psoriasis. (Never = 1, rarely = 2, Sometimes = 3, Often = 4)
| Participants | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Number of Participants Whose Frequency of Avoiding Sexual Activity is Either Never or Rarely Limited by Genital Psoriasis in the Sexual Activity Avoidance Subscale Score of the Genital Psoriasis Sexual Impact Scale (GPSIS) | 9 | 23 |
DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: 1) Symptoms and feelings 2) Daily activities 3) Leisure 4) Work and school 5) Personal relationships 6) Treatment. Response categories include: 0 = not at all; 1 = a little; 2 = a lot; 3 = very much; "not relevant" responses scored as "0" and total score range of 0 to 30; higher scores indicate poor quality of life. Least Square (LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model with treatment, baseline body surface area (BSA) category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
| units on a scale | Placebo | Ixekizumab Q2W |
|---|---|---|
| Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score | -1.4 ± 0.62 | -9.7 ± 0.59 |
mGPASI determines participants psoriasis severity in the genital region at a given time point yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. scoring index incorporates the degree of erythema (or redness), induration (or thickness), and scaling) of the genital plaques as well as erosion, fissure, and/or ulcer as a product of the genital area involved. LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
| units on a scale | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Change From Baseline in Modified Genital Psoriasis Area and Severity Index (mGPASI) Score | -3.9 ± 1.56 | -23.9 ± 1.48 |
Patient's Global Assessment of Genital Psoriasis (PatGA-Genital) is a participant-administered, single-item scale on which participants are asked to rank the severity of their genital psoriasis "today" by circling a number on a 0 to 5 NRS, as follows: from 0 (clear), no genital psoriasis; to 5 (severe).
| Participants | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Number of Participants With at Least a 2-Point Change in Patient's Global Assessment of Genital Psoriasis (PatGA-Genital) | 11 | 51 |
SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, \& baseline value and modified baseline observation carried forward (mBOCF) imputation method.
| units on a scale | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Change From Baseline on the Short-Form Health Survey (SF-36) Physical Component Summary (PCS) | 0.687 ± 0.7998 | 5.193 ± 0.7942 |
SF-36 is a participant-reported outcome measure evaluating a participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the MCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. Least Squares Mean (LS Mean) was calculated using Analysis of covariance (ANCOVA) model with treatment, baseline BSA category, \& baseline value and modified baseline observation carried forward (mBOCF) imputation method.
| units on a scale | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Change From Baseline on the Short-Form Health Survey (SF-36) Mental Component Summary (MCS) | 2.186 ± 0.7333 | 3.982 ± 0.7281 |
GPSS is a participant's-administered assessment of 8 symptoms: itch, pain, discomfort, stinging, burning, redness, scaling, and cracking. Each respondent was asked to answer the questions based on the psoriasis symptoms in his or her genital area. The overall severity for each individual genital psoriasis symptom is indicated by selecting the number from an Numeric Rating Scale (NRS) of 0 to 10 that best describes the worst level of each symptom in the genital area in the past 24 hours, where 0 (no severity) and 10 (worst imaginable severity). total score ranges from 0 (no severity) - 80 (worst imaginable severity) LS Mean was calculated using MMRM model with treatment, baseline BSA category, baseline value, visit, treatment-by-visit, and baseline value-by-visit interactions as fixed effects.
| units on a scale | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| Total Score | -2.82 ± 2.190 | -31.57 ± 2.070 |
| Itch | -0.21 ± 0.290 | -4.02 ± 0.274 |
| Pain | -0.34 ± 0.294 | -3.84 ± 0.278 |
| Discomfort | -0.42 ± 0.298 | -4.27 ± 0.282 |
| Stinging | -0.51 ± 0.298 | -3.74 ± 0.281 |
| Burning | -0.53 ± 0.289 | -3.73 ± 0.273 |
| Redness | -0.63 ± 0.287 | -4.45 ± 0.272 |
| Scaling | -0.02 ± 0.273 | -3.80 ± 0.259 |
| Cracking | -0.19 ± 0.280 | -3.74 ± 0.264 |
sPGA of Genitalia score is based on a combination of erythema and the secondary features (plaque elevation and/or scale). For the analysis of responses, the participant's psoriasis was assessed as follows: 0 = clear,1 = minimal, 2 = mild, 3 = moderate, 4 = severe, 5 = very severe. sPGA of Genitalia (0,1) : A sPGA of Genitalia assessed as either 0 or 1.
| Participants | Placebo | Ixekizumab 80mg Q2W |
|---|---|---|
| TE-ADA positive | — | 5 |
| TE-ADA negative | 6 | 50 |
| NAb inconclusive | — | 5 |
Collected over Up to 667 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Blinded Treatment Period | 0/74 (0%) | 1/74 (1.4%) | 19/74 (25.7%) |
| Ixekizumab 80 mg Q2W - Blinded Treatment Period | 0/75 (0%) | 0/75 (0%) | 21/75 (28%) |
| Placebo/Ixekizumab 80mg Q4W - Open Label Treatment Period | 0/65 (0%) | 2/65 (3.1%) | 28/65 (43.1%) |
| Ixekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label Treatment | 0/74 (0%) | 5/74 (6.8%) | 27/74 (36.5%) |
| Placebo - Post Treatment Follow-up | 0/1 (0%) | 0/1 (0%) | 0/1 (0%) |
| Ixeqizumab 80mg Q2W - Post Treatment Follow-up Period | 0/49 (0%) | 2/49 (4.1%) | 1/49 (2%) |
| Ixekizumab 80mg Q4W - Post Treatment Follow-up | 0/78 (0%) | 1/78 (1.3%) | 0/78 (0%) |
| Event | Placebo - Blinded Treatment Period | Ixekizumab 80 mg Q2W - Blinded Treatment Period | Placebo/Ixekizumab 80mg Q4W - Open Label Treatment Period | Ixekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label Treatment | Placebo - Post Treatment Follow-up | Ixeqizumab 80mg Q2W - Post Treatment Follow-up Period | Ixekizumab 80mg Q4W - Post Treatment Follow-up |
|---|---|---|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/74 | 0/75 | 0/65 | 0/74 | 0/1 | 1/49 | 0/78 |
| CellulitisInfections and infestations | 0/74 | 0/75 | 1/65 | 0/74 | 0/1 | 1/49 | 0/78 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/74 | 0/75 | 0/49 | 1/56 | 0/1 | 0/49 | 0/78 |
| Extradural haematomaInjury, poisoning and procedural complications | 0/74 | 0/75 | 1/65 | 0/74 | 0/1 | 0/49 | 0/78 |
| ColitisGastrointestinal disorders | 0/74 | 0/75 | 0/65 | 1/74 | 0/1 | 0/49 | 0/78 |
| Pancreatitis acuteGastrointestinal disorders | 1/74 | 0/75 | 0/65 | 0/74 | 0/1 | 0/49 | 0/78 |
| CholelithiasisHepatobiliary disorders | 0/74 | 0/75 | 0/65 | 1/74 | 0/1 | 0/49 | 0/78 |
| Escherichia bacteraemiaInfections and infestations | 0/74 | 0/75 | 0/65 | 1/74 | 0/1 | 0/49 | 0/78 |
| SepsisInfections and infestations | 0/74 | 0/75 | 0/65 | 1/74 | 0/1 | 0/49 | 0/78 |
| Suicide attemptPsychiatric disorders | 0/74 | 0/75 | 0/65 | 1/74 | 0/1 | 0/49 | 0/78 |
| Event | Placebo - Blinded Treatment Period | Ixekizumab 80 mg Q2W - Blinded Treatment Period | Placebo/Ixekizumab 80mg Q4W - Open Label Treatment Period | Ixekizumab 80mg Q2W/Ixekizumab 80mg Q4W - Open Label Treatment | Placebo - Post Treatment Follow-up | Ixeqizumab 80mg Q2W - Post Treatment Follow-up Period | Ixekizumab 80mg Q4W - Post Treatment Follow-up |
|---|---|---|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/74 | 12/75 | 10/65 | 6/74 | 0/1 | 0/49 | 0/78 |
| Injection site reactionGeneral disorders | 0/74 | 5/75 | 10/65 | 3/74 | 0/1 | 0/49 | 0/78 |
| NasopharyngitisInfections and infestations | 4/74 | 2/75 | 9/65 | 7/74 | 0/1 | 0/49 | 0/78 |
| Vulvovaginal discomfortReproductive system and breast disorders | 0/74 | 0/75 | 0/65 | 0/74 | — | 1/11 | 0/21 |
| HeadacheNervous system disorders | 4/74 | 3/75 | 2/65 | 6/74 | 0/1 | 0/49 | 0/78 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/74 | 0/75 | 0/65 | 5/74 | 0/1 | 0/49 | 0/78 |
| Vulvovaginal candidiasisInfections and infestations | 0/74 | 0/75 | 1/16 | 0/18 | 0/1 | 0/49 | 0/78 |
| Bacterial vaginosisInfections and infestations | 0/74 | 0/75 | 0/16 | 1/18 | 0/1 | 0/49 | 0/78 |
| Vulvovaginal mycotic infectionInfections and infestations | 0/74 | 0/75 | 0/16 | 1/18 | 0/1 | 0/49 | 0/78 |
| DysmenorrhoeaReproductive system and breast disorders | 0/74 | 0/75 | 0/16 | 1/18 | 0/1 | 0/49 | 0/78 |
| Age, Continuous(years) | Placebo | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|
| Mean | 44.4 ± 12.55 | 43.1 ± 12.95 | 43.7 ± 12.72 |
| Sex: Female, Male(Participants) | Placebo | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|
| Female | 17 | 19 | 36 |
| Male | 57 | 56 | 113 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 13 | 27 |
| Not Hispanic or Latino | 57 | 60 | 117 |
| Unknown or Not Reported | 3 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Placebo | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 7 | 3 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 0 | 2 |
| White | 64 | 67 | 131 |
| More than one race | 1 | 4 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|
| Canada | 16 | 13 | 29 |
| Puerto Rico | 4 | 7 | 11 |
| Austria | 4 | 4 | 8 |
| Netherlands | 2 | 3 | 5 |
| Turkey | 3 | 4 | 7 |
| Belgium | 3 | 4 | 7 |
| United States | 31 | 31 | 62 |
| Australia | 11 | 9 | 20 |
| sPGA of Genitalia(units on a scale) | Placebo | Ixekizumab 80mg Q2W | Total |
|---|---|---|---|
| Mean | 3.5 ± 0.53 | 3.4 ± 0.61 | 3.4 ± 0.57 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Apr 2016, a primary completion of Feb 2017 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2018, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab